Leveraging predictive analytics to estimate clinical trial success

Newsroom

All news

Leveraging predictive analytics to estimate clinical trial success

Estimation of the success likelihood of a clinical trial plays a vital role in determining the time and investment it takes to bring efficacious drug treatment to patients to cure and manage disease. 

 

In an interview with CIO Applications, a Silicon Valley-based tech magazine, Blanca Baez, SVP, Global Head of Pharma & Biotech, and Armin Schneider, SVP of Scientific & Medical Affairs of Molecular Health, share their insights on how the company helps in making unbiased evidence-based clinical development and portfolio  decisions with its technology platform branded MH Predict, by converting clinical and molecular data and medical knowledge into actionable information. Read more at: https://www.molecularhealth.com/wp-content/uploads/2020/05/MH_Predict_Interview_CIO_Applications_6-2020.pdf

Important COVID-19 Update from Molecular Health

Newsroom

All news

Important COVID-19 Update from Molecular Health

Dear customers and partners,

 

at Molecular Health we share the global concern over the coronavirus pandemic. We want to assure you that we will maintain uninterrupted operation during these challenging times.

 

Our principal investor is Dievini, the investment company of Dietmap Hopp, focusing on innovative biotechnological products and technologies. Also in Dievini’s investment portfolio is the Tübingen-based company CureVac AG, currently in the news as they ramp up their efforts to develop an mRNA-based coronavirus vaccine.

 

Molecular Health’s software identifies the best drugs for individual cancer patients, and our customers – hospitals, laboratories, and patients – depend on us to continue to provide high-quality interpretation of tumours, because, especially now, all patients are entitled to the best healthcare possible.

Our software also enables pharmaceutical companies to improve their research and design more effective clinical trials.

 

In these times of massive transformation, we at Molecular Health have adapted our processes to protect our staff, our partners, and especially those in risk groups:

  • We are keeping our team safe: all our employees are working from home office.
  • We strongly support social distancing: all business meetings with customers and partners are now held virtually. Reach out to your contact person at Molecular Health if you have any questions about an upcoming appointment.
  • We are prepared: if any of our employees should become ill, we will do whatever it takes to remain productive and deliver our services seamlessly.

Thank you for your continued partnership, and please don’t hesitate to contact us if you have any questions or concerns.

 

With kind regards from Heidelberg,

Dr. Friedrich von Bohlen

CEO

Request whitepaper on Tumor Mutational Burden (TMB)

Newsroom

All news

Whitepaper: Tumor Mutational Burden (TMB)

The Tumor Mutational Burden (TMB) is a biomarker that shows the total number of somatic and coding mutations, base substitutions, insertions or measures deletions (indels) per megabase (Mb) of the examined genome. It must be validated individually for each indication. Strongly mutated tumors are more likely to generate neoantigens that are recognized as foreign by immune cells. Tumors with a high TMB can therefore have a high immunogenicity. Read more about why TMB is relevant in the context of cancer immunotherapy in our whitepaper: https://www.molecularhealth.com/us/tumor-mutational-burden-us/

Molecular Health is featured in DrugBank case study on data-driven technologies

Newsroom

All news

Molecular Health is featured in DrugBank case study on data-driven technologies

Molecular Health is featured in a case study of DrugBank, the world’s largest online database of drug and drug target information. DrugBank is a widely used data source for companies working in the pharmaceutical, healthcare, and technology space. The data integrates seamlessly into in-house products to enhance outcomes for data-driven decision making. Read more at: DrugBank case study

Molecular Health – Transforming Cancer Treatment to Improve Patient Lives

Newsroom

All news

Molecular Health – Transforming Cancer Treatment to Improve Patient Lives

Each cancer diagnosis is unique, so individualized treatment is critical. With its Molecular Health Guide (MH Guide) powered by SAP HANA®,

Molecular Health is transforming cancer treatment. The solution mines and analyzes a wealth of data on each patient, their cancer, and relevant medical

data to help oncologists quickly identify the most promising therapies. By advancing personalized, evidence-based medicine, Molecular Health is transforming cancer treatment to help improve.

 

https://www.molecularhealth.com/wp-content/uploads/2020/01/SAP-Story-about-MH-Guide.pdf

Molecular Health holds industry symposium at DGP Annual Meeting in Frankfurt

Newsroom

All news

Molecular Health holds industry symposium at DGP Annual Meeting in Frankfurt

Molecular Health is sponsor and exhibitor at the 103rd Annual Meeting of the German Society of Pathology in Frankfurt.

It holds a lunch symposium on „Scaling the analysis and interpretation of NGS data with the medical device MH Guide in a clinical setting“ (Saturday, June 15, 12:15-1:45 pm). Prof. M. Kanai (Kyoto University Hospital) and Prof. M. Hummel (Charité Institute of Pathology) share their experiences with MH Guide in daily clinical routine.

http://www.professionalabstracts.com/pathologie2019/Iplanner/#/grid

MH Guide for labs: Augment your annotations quickly

Newsroom

All news

MH Guide for labs: Augment your annotations quickly

Benefit from our software-aided interpretations for personalized cancer treatment

• Latest and comprehensive clinical evidence gathered from top publications/databases
• Oncologist/pathologist reviewed annotations that include treatment options
• Seamless integration into existing lab workflow
• Intuitive UI/UX
• Cloud-based portal for rapid and secure processing

Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Newsroom

All news

Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Abstract

Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of pharmacological target adverse‐event (TAE) profiles to predict AEs on US Food and Drug Administration (FDA) drug labels at least 4 years after approval. TAE profiles were generated by aggregating AEs from the FDA adverse event reporting system (FAERS) reports and the FDA drug labels for drugs that hit a common target. A genetic algorithm (GA) was used to choose the adverse event (AE) case count (N), disproportionality score in FAERS (proportional reporting ratio (PRR)), and percent of comparator drug labels with an AE to maximize F‐measure. With FAERS data alone, precision, recall, and specificity were 0.57, 0.78, and 0.61, respectively. After including FDA drug label data, precision, recall, and specificity improved to 0.67, 0.81, and 0.71, respectively. Eighteen of 23 (78%) post-market label changes were identified correctly. TAE analysis shows promise as a method to predict AEs at the time of drug approval.

Molecular Health launches MH Mendel for the genetic diagnosis of hereditary diseases

Newsroom

All news

Molecular Health launches MH Mendel for the genetic diagnosis of hereditary diseases

• MH Mendel combines the most relevant information for the diagnosis of hereditary diseases  
• MH Mendel helps patients and supports physicians through most modern and comprehensive precision medicine technologies and expertise 
• MH Mendel becomes an integral part of IVD registered Molecular Health Guide® 3.0

 

Heidelberg, Germany and Boston, USA – June 11, 2018 – Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer cancer treatment options based on its proprietary Dataome® technology platform, has introduced Molecular Health Guide® Mendel (MH Mendel) as part of the established Molecular Health Guide® (MH Guide), a comprehensive software solution for precision medicine. MH Mendel, an integral part of the MH Guide 3.0, a registered IVD product, supports human geneticists in creating a diagnostic report based on their own variant classifications. MH Mendel combines the information that is most relevant for the diagnosis of hereditary diseases. Data from a variety of sources are provided to help human geneticists to assess and classify variants detected in their patients. MH Mendel includes population frequencies, reported clinical significance, and functional impact predictions for a plethora of variants. For analysis of germline variants associated with hereditary diseases, MH Mendel supports human geneticists in managing their own variant classifications and interpretations as well as in creating diagnostic reports. ”Genetic tests can reveal a predisposition to rare hereditary diseases. Today some hereditary diseases can be managed. Early detection and precise understanding is important to initiate treatment and to prevent avoidable irreparable defects. Results of genetic tests analyzed and evaluated by MH Mendel can reveal ae predisposition to diseases and help physicians to find the exact molecular cause and to create a personalized diagnostic report for each patient “, says Dr. Stephan Brock, CTO of Molecular Health. “We are glad that with MH Mendel we can now help patients and support physicians with our advanced and highly curated and integrated precision medicine technologies and expertise.” 

Molecular Health receives grant from Bill & Melinda Gates Foundation

Newsroom

All news

Molecular Health receives grant from Bill & Melinda Gates Foundation

Molecular Health to pursue drug repurposing in tuberculosis treatment and perinatal complications 

 

Molecular Health receives grant from Bill & Melinda Gates Foundation 

Heidelberg, Germany/Boston, MA, May 16, 2018. Molecular Health announces it was awarded a grant from the Bill & Melinda Gates Foundation. Through the program enabled by the grant, Molecular Health (MH) will leverage computational biomedicine technology and domain expertise captured in MH core assets, Dataome® knowledgebase and MH Effect™ software, to help find shorter, more effective and better-tolerated treatment regimens for TB, and to explore ways to address perinatal complications in developing countries. Dataome® is MH’s biomedicine knowledgebase with comprehensive, current and curated clinico-molecular data and information on targets, molecules, diseases, variants, pathways, drugs and outcomes and will be utilized to identify treatment improvement opportunities in these two areas of unmet need, deriving novel insights on drug outcomes from other areas, such as immuno-oncology. MH Effect™ will allow MH experts to tap onto millions of patient records on drug outcomes to efficiently draw and test treatment hypotheses. Blanca Baez, Global Head of Pharma & Biotech at Molecular Health, expressed: “Our value proposition to drug discovery and drug development is to employ highly specialized in silico research and machine learning techniques to speedily generate, prove and disprove hypotheses for novel, repurposed or combined drug treatments to improve efficacy and safety in specific patient profiles. We do this through clinico-molecular analytics on drug target, mode of action and disease pathways. This grant allows us to continue delivering on this promise.”